Top

International Journal of Clinical Oncology

Published in:

21-02-2024 | Gastric Cancer | Original Article

Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression

Authors: Zijun Guo, Lin Guo

Published in: International Journal of Clinical Oncology | Issue 4/2024

Abstract

Background

Gastric cancer (GC) is a malignant tumor with a high mortality rate, and thus, it is necessary to explore molecular mechanisms underlying its progression. While replication factor C subunit 3 (RFC3) has been demonstrated to function as an oncogene in many cancers, its role in GC remains unclear.

Methods

Tumor tissues were collected from clinical GC patients, and the expression of RFC3 was analyzed. NCI-N87 and HGC-27 cells were infected with lentivirus sh-RFC3 to knock down RFC3 expression. RFC3 expression levels were determined, in addition to cell biological behaviors both in vitro and in vivo. The relationship between RFC3 and the YAP1/TEAD signaling pathway was detected by dual luciferase reporter assay.

Results

RFC3 was upregulated in GC tumor tissues. RFC3 knockdown inhibited cell proliferation, promoted cell apoptosis of GC cells, and suppressed cell migration and invasion. Moreover, depleted RFC3 suppressed tumor growth and metastasis in vivo. Mechanistically, the YAP1/TEAD axis activated RFC3 expression transcriptionally by binding to the RFC3 promoter.

Conclusions

RFC3 was transcriptional activated by the YAP1/TEAD signaling pathway, thus promoting GC progression. RFC3 may be a promising therapeutic target for GC.

Smyth EC, Nilsson M, Grabsch HI et al (2020) Gastric cancer. Lancet 396(10251):635–648. https://doi.org/10.1016/s0140-6736(20)31288-5CrossRefPubMed

Digklia A, Wagner AD (2016) Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol 22(8):2403–2414. https://doi.org/10.3748/wjg.v22.i8.2403CrossRefPubMedPubMedCentral

Huang C, Yuan W, Lai C et al (2020) EphA2-to-YAP pathway drives gastric cancer growth and therapy resistance. Int J Cancer 146(7):1937–1949. https://doi.org/10.1002/ijc.32609CrossRefPubMed

Zanconato F, Forcato M, Battilana G et al (2015) Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol 17(9):1218–1227. https://doi.org/10.1038/ncb3216CrossRefPubMedPubMedCentral

Li H, Li X, Jing X et al (2018) Hypoxia promotes maintenance of the chondrogenic phenotype in rat growth plate chondrocytes through the HIF-1α/YAP signaling pathway. Int J Mol Med 42(6):3181–3192. https://doi.org/10.3892/ijmm.2018.3921CrossRefPubMedPubMedCentral

Machado MV, Michelotti GA, Pereira TA et al (2015) Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J Hepatol 63(4):962–970. https://doi.org/10.1016/j.jhep.2015.05.031CrossRefPubMedPubMedCentral

Zhang J, Zhou Y, Tang PMK et al (2019) Mechanotransduction and cytoskeleton remodeling shaping YAP1 in gastric tumorigenesis. Int J Mol Sci. https://doi.org/10.3390/ijms20071576CrossRefPubMedPubMedCentral

Wu S, Liu Y, Zheng Y et al (2008) The TEAD/TEF family protein scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell 14(3):388–398. https://doi.org/10.1016/j.devcel.2008.01.007CrossRefPubMed

Zhao B, Ye X, Yu J et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22(14):1962–1971. https://doi.org/10.1101/gad.1664408CrossRefPubMedPubMedCentral

10.

Zhou Y, Huang T, Zhang J et al (2017) TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. Oncogene 36(47):6518–6530. https://doi.org/10.1038/onc.2017.257CrossRefPubMedPubMedCentral

11.

Lockwood WW, Thu KL, Lin L et al (2012) Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clin Cancer Res 18(7):1936–1946. https://doi.org/10.1158/1078-0432.Ccr-11-1431CrossRefPubMedPubMedCentral

12.

Shen H, Cai M, Zhao S et al (2014) Overexpression of RFC3 is correlated with ovarian tumor development and poor prognosis. Tumour Biol 35(10):10259–10266. https://doi.org/10.1007/s13277-014-2216-2CrossRefPubMed

13.

Yuan Y, Park J, Feng A et al (2020) YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity. Nat Commun 11(1):1472. https://doi.org/10.1038/s41467-020-15301-0CrossRefPubMedPubMedCentral

14.

Yu S, Zhang Y, Li Q et al (2019) CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer. Cell Death Dis 10(12):949. https://doi.org/10.1038/s41419-019-2168-yCrossRefPubMedPubMedCentral

15.

Liu Z, Li J, Ding Y et al (2022) USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer. Oncogene 41(18):2555–2570. https://doi.org/10.1038/s41388-022-02267-0CrossRefPubMed

16.

Qin Y, Pei Z, Feng Z et al (2021) Oncogenic activation of YAP signaling sensitizes ferroptosis of hepatocellular carcinoma via ALOXE3-mediated lipid peroxidation accumulation. Front Cell Dev Biol 9:751593. https://doi.org/10.3389/fcell.2021.751593CrossRefPubMedPubMedCentral

17.

Lv X, He C, Huang C et al (2020) Reprogramming of ovarian granulosa cells by YAP1 leads to development of high-grade cancer with mesenchymal lineage and serous features. Sci Bull (Beijing) 65(15):1281–1296. https://doi.org/10.1016/j.scib.2020.03.040CrossRefPubMed

18.

Hasegawa T, Sugihara T, Hoshino Y et al (2021) Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein survivin in a light-independent manner. Oncol Lett 22(4):703. https://doi.org/10.3892/ol.2021.12964CrossRefPubMedPubMedCentral

19.

Luis M, Tavares A, Carvalho LS et al (2013) Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol 19(38):6383–6397. https://doi.org/10.3748/wjg.v19.i38.6383CrossRefPubMedPubMedCentral

20.

Hatfield KJ, Reikvam H, Bruserud Ø (2014) Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert Opin Ther Targets 18(11):1237–1251. https://doi.org/10.1517/14728222.2014.957671CrossRefPubMed

21.

Shen H, Xu J, Zhao S et al (2015) ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation. Int J Clin Exp Pathol 8(8):8968–8975PubMedPubMedCentral

22.

Yao Z, Hu K, Huang H et al (2015) shRNA-mediated silencing of the RFC3 gene suppresses hepatocellular carcinoma cell proliferation. Int J Mol Med 36(5):1393–1399. https://doi.org/10.3892/ijmm.2015.2350CrossRefPubMed

23.

Liu Z, Ding Y, Ye N et al (2016) Direct activation of bax protein for cancer therapy. Med Res Rev 36(2):313–341. https://doi.org/10.1002/med.21379CrossRefPubMed

24.

Hardwick JM, Soane L (2013) Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a008722CrossRefPubMedPubMedCentral

25.

Notarbartolo M, Cervello M, Poma P et al (2004) Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 11(1):133–136PubMed

26.

Tong QS, Zheng LD, Wang L et al (2005) Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 12(5):509–514. https://doi.org/10.1038/sj.cgt.7700813CrossRefPubMed

27.

Oliver TG, Grasfeder LL, Carroll AL et al (2003) Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 100(12):7331–7336. https://doi.org/10.1073/pnas.0832317100CrossRefPubMedPubMedCentral

28.

Spurgers KB, Gold DL, Coombes KR et al (2006) Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 281(35):25134–25142. https://doi.org/10.1074/jbc.M513901200CrossRefPubMed

29.

Mac SM, D’Cunha CA, Farnham PJ (2000) Direct recruitment of N-myc to target gene promoters. Mol Carcinog 29(2):76–86CrossRefPubMed

30.

Kang W, Cheng AS, Yu J et al (2016) Emerging role of Hippo pathway in gastric and other gastrointestinal cancers. World J Gastroenterol 22(3):1279–1288. https://doi.org/10.3748/wjg.v22.i3.1279CrossRefPubMedPubMedCentral

Title: Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression
Authors: Zijun Guo
Lin Guo
Publication date: 21-02-2024
Publisher: Springer Nature Singapore
Keywords: Gastric Cancer
Gastric Cancer
Published in: International Journal of Clinical Oncology / Issue 4/2024
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-024-02478-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2024

Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan

Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021

Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer

Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis

Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy

Hydronephrosis severity as a predictor of postoperative renal function decline following laparoscopic radical nephroureterectomy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer